scholarly journals Enhanced anti-tumor therapeutic efficacy of DNA vaccine by fusing the E7 gene to BAFF in treating human papillomavirus-associated cancer

Oncotarget ◽  
2017 ◽  
Vol 8 (20) ◽  
pp. 33024-33036 ◽  
Author(s):  
Chao-Chih Wu ◽  
Fang-Cih Wu ◽  
Yun-Tin Hsu ◽  
Yu-Chia Hsiao ◽  
Yuh-Cheng Yang ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Dna Vaccine ◽  
Therapeutic Efficacy ◽  
E7 Gene

Enhanced Therapeutic Effects Conferred by an Experimental DNA Vaccine Targeting Human Papillomavirus-Induced Tumors

2013 ◽  
Vol 24 (10) ◽  
pp. 861-870 ◽  
Author(s):  
Mariana O. Diniz ◽  
Francisco A.M.O. Cariri ◽  
Luana R.M.M. Aps ◽  
Luís C.S. Ferreira
Keyword(s):  
Human Papillomavirus ◽  
Dna Vaccine ◽  
Therapeutic Effects ◽  
Induced Tumors

Combined immunization with fusion genes of mutated E7 gene of human papillomavirus type 16 did not enhance antitumor effect

2005 ◽  
Vol 7 (6) ◽  
pp. 696-707 ◽  
Author(s):  
Dana Pokorná ◽  
Jana Macková ◽  
Martina Dušková ◽  
Šimon Rittich ◽  
Viera Ludvíková ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Antitumor Effect ◽  
Fusion Genes ◽  
Human Papillomavirus Type 16 ◽  
E7 Gene

Development of a novel viral DNA vaccine against human papillomavirus: AcHERV-HP16L1

Vaccine ◽  
2010 ◽  
Vol 28 (6) ◽  
pp. 1613-1619 ◽  
Author(s):  
Hee-Jung Lee ◽  
Nuri Park ◽  
Hee-Jeong Cho ◽  
Jong Kwang Yoon ◽  
Nguyen Dinh Van ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Dna Vaccine ◽  
Viral Dna

scholarly journals Immune Responses and Therapeutic Antitumor Effects of an Experimental DNA Vaccine Encoding Human Papillomavirus Type 16 Oncoproteins Genetically Fused to Herpesvirus Glycoprotein D

2010 ◽  
Vol 17 (10) ◽  
pp. 1576-1583 ◽  
Author(s):  
Mariana O. Diniz ◽  
Marcio O. Lasaro ◽  
Hildegund C. Ertl ◽  
Luís C. S. Ferreira
Keyword(s):  
Human Papillomavirus ◽  
T Cell ◽  
Immune Responses ◽  
Dna Vaccine ◽  
T Cell Responses ◽  
Glycoprotein D ◽  
Antitumor Effects ◽  
Hpv 16 ◽  
Human Papillomavirus Type 16 ◽  
Cell Responses

ABSTRACT Recombinant adenovirus or DNA vaccines encoding herpes simplex virus type 1 (HSV-1) glycoprotein D (gD) genetically fused to human papillomavirus type 16 (HPV-16) oncoproteins (E5, E6, and E7) induce antigen-specific CD8+ T-cell responses and confer preventive resistance to transplantable murine tumor cells (TC-1 cells). In the present report, we characterized some previously uncovered aspects concerning the induction of CD8+ T-cell responses and the therapeutic anticancer effects achieved in C57BL/6 mice immunized with pgD-E7E6E5 previously challenged with TC-1 cells. Concerning the characterization of the immune responses elicited in mice vaccinated with pgD-E7E6E5, we determined the effect of the CD4+ T-cell requirement, longevity, and dose-dependent activation on the E7-specific CD8+ T-cell responses. In addition, we determined the priming/boosting properties of pgD-E7E6E5 when used in combination with a recombinant serotype 68 adenovirus (AdC68) vector encoding the same chimeric antigen. Mice challenged with TC-1 cells and then immunized with three doses of pgD-E7E6E5 elicited CD8+ T-cell responses, measured by intracellular gamma interferon (IFN-γ) and CD107a accumulation, to the three HPV-16 oncoproteins and displayed in vivo antigen-specific cytolytic activity, as demonstrated with carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled target cells pulsed with oligopeptides corresponding to the H-2Db -restricted immunodominant epitopes of the E7, E6, or E5 oncoprotein. Up to 70% of the mice challenged with 5 × 105 TC-1 cells and immunized with pgD-E7E6E5 controlled tumor development even after 3 days of tumor cell challenge. In addition, coadministration of pgD-E7E6E5 with DNA vectors encoding pGM-CSF or interleukin-12 (IL-12) enhanced the therapeutic antitumor effects for all mice challenged with TC-1 cells. In conclusion, the present results expand our previous knowledge on the immune modulation properties of the pgD-E7E6E5 vector and demonstrate, for the first time, the strong antitumor effects of the DNA vaccine, raising promising perspectives regarding the development of immunotherapeutic reagents for the control of HPV-16-associated tumors.

Sequence variation in the E7 gene of human papillomavirus type 18 in tumor and non-tumor patients and antibody response to a conserved seroreactive epitope

1993 ◽  
Vol 53 (2) ◽  
pp. 257-259 ◽  
Author(s):  
J. Ter Meulen ◽  
A. C. Schweigler ◽  
H. C. Eberhardt ◽  
J. Luande ◽  
H. N. Mgaya ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Antibody Response ◽  
Sequence Variation ◽  
Tumor Patients ◽  
E7 Gene

A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity

Vaccine ◽  
2001 ◽  
Vol 19 (30) ◽  
pp. 4276-4286 ◽  
Author(s):  
Wolfram Osen ◽  
Tanja Peiler ◽  
Peter Öhlschläger ◽  
Sandra Caldeira ◽  
Stefan Faath ◽  
...  
Keyword(s):  
T Cells ◽  
Human Papillomavirus ◽  
Dna Vaccine ◽  
Cytotoxic T Cells ◽  
Hpv 16 ◽  
Human Papillomavirus Type 16 ◽  
Transforming Activity ◽  
E7 Oncogene
Sign in / Sign up

Export Citation Format

Share Document